E2 ModerateModerate confidencePEM unclearMechanisticPeer-reviewedReviewed
Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome.
Loebel, Madlen, Grabowski, Patricia, Heidecke, Harald et al. · Brain, behavior, and immunity · 2016 · DOI
Quick Summary
Researchers tested whether ME/CFS patients have unusually high levels of antibodies (immune proteins) that attack nerve signaling receptors in the body. They found that about 30% of ME/CFS patients had elevated antibodies against certain receptors involved in adrenaline and acetylcholine signaling—chemicals that control heart rate, breathing, and other automatic body functions. Importantly, patients who received rituximab (a treatment that depletes B cells) and improved showed decreases in these antibody levels, suggesting a possible link between these antibodies and disease activity.
Why It Matters
This study provides evidence for an autoimmune mechanism in ME/CFS by identifying specific autoantibodies that correlate with immune activation and autonomic symptoms. The finding that antibody levels decline with effective B-cell depletion therapy suggests a potential biological marker for predicting treatment response, which could guide personalized clinical management and validate immunotherapeutic approaches in ME/CFS.
Observed Findings
- Approximately 29.5% of ME/CFS patients had elevated antibodies against one or more M1-5 acetylcholine or β adrenergic receptors compared to healthy controls.
- Antibodies against β2, M3, and M4 receptors were significantly elevated in patients; antibodies against α adrenergic, dopamine, serotonin, angiotensin, and endothelin receptors were not.
- Patients with high β2 antibodies had significantly higher frequencies of activated HLA-DR+ T cells and more frequent thyreoperoxidase and anti-nuclear antibodies.
- In rituximab responders with prolonged B-cell depletion, β2 and M4 receptor autoantibody levels significantly declined; no significant decline occurred in non-responders.
Inferred Conclusions
- Autoantibodies against β adrenergic and M acetylcholine receptors represent a potential biomarker for identifying ME/CFS patients who may respond to B-cell depleting therapy.
- These receptor autoantibodies likely activate B and T cell populations, contributing to persistent immune activation in ME/CFS.
- Dysregulation of acetylcholine and adrenergic signaling mediated by these autoantibodies may explain autonomic and other clinical symptoms characteristic of ME/CFS.
Remaining Questions
- Do these autoantibodies have functional effects on receptor signaling and autonomic function, or are they epiphenomenal markers of B-cell activation?
- What triggers the initial breakdown of tolerance to these specific neurotransmitter receptors, and why do only ~30% of ME/CFS patients develop them?
What This Study Does Not Prove
This study does not prove that these autoantibodies directly cause ME/CFS symptoms or dysfunction; it demonstrates correlation and association. The study is not a functional assay—it does not show that these antibodies functionally impair receptor signaling in vivo. The cross-sectional Berlin cohort design cannot establish causation, and the small rituximab sample (n=25) limits generalizability of treatment-response findings.
Tags
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionExploratory Only
Symptom:FatigueOrthostatic Intolerance
Metadata
- DOI
- 10.1016/j.bbi.2015.09.013
- PMID
- 26399744
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.